title: Cyclophosphamide therapy in granulomatous hepatitis: cure or culprit?
abstract: Three months after diagnosis of Wegener granulomatosis, an 84-year-old woman who was treated with cyclophosphamide (CPY) and prednisone developed deranged liver function tests (LFTs). Treatment with CPY was held, which led to normalization of LFTs, but after reinitiating of CPY, LFTs started increasing. Liver biopsy showed noncaseating epithelioid granulomas within liver lobules consistent with granulomatous hepatitis. Patient died within 2 months secondary to liver failure. This elevation of transaminases was considered to be secondary to CPY-induced hepatotoxicity. Involvement of liver in patients with Wegener granulomatosis is seen but it presents with necrotizing granulomatous vasculitis. CPY-induced hepatitis is an extremely rare phenomenon with only 1 case reported in literature. Clinicians and hepatologists should be aware of this potentially serious complication when CPY therapy is initiated. Baseline LFTs and periodic assessment are recommended before and during treatment with CPY.
authors.affiliation: Department of Medicine, Faxton-St. Luke's Hospital, Utica, NY 13502, USA. drdranil@yahoo.com
authors.forename: Anil
authors.initials: A
authors.lastname: Patel
authors.forename: Anush
authors.initials: A
authors.lastname: Patel
authors.forename: Sonal
authors.initials: S
authors.lastname: Patel
authors.forename: Priyanka
authors.initials: P
authors.lastname: Jalandhara
authors.forename: Pratapji
authors.initials: P
authors.lastname: Thakor
mesh_terms: D000369:Aged, 80 and over; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006099:Granuloma / Q000139:chemically induced* / Q000175:diagnosis; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone